Related Experiment Video
Updated: Aug 12, 2026
Mouse Models for Graft Arteriosclerosis
Published on: May 14, 2013
RAR gamma agonists inhibit proliferation of vascular smooth muscle cells
1Department of Internal Medicine, University of Texas-Health Science Center of Houston, 77030, USA.
Abstract:
The multifactorial and unpredictable nature of human restenosis will probably necessitate interventional strategies that target multiple processes involved in neointimal proliferation. Retinoids represent a growing class of pleiotropic biologic response modifiers with demonstrable efficacy in managing several pathologic conditions pertaining to neointimal proliferation. However, retinoid treatment is associated with a high incidence of adverse effects. The action of all-trans-retinoic acid is mediated by two families of nuclear receptors, RARs and RXRs, each containing three isoforms alpha, beta, and gamma. Because synthetic retinoids that are receptor and function specific have been shown to differ from each other by several orders of magnitude in their potencies and are associated with limited adverse effects, we examined the effect of synthetic retinoids on serum- and serotonin-induced vascular smooth muscle cell (VSMC) proliferation. Naturally occurring retinoids were used as controls. All-trans-retinoic acid at nanomolar concentrations inhibited smooth muscle cell proliferation. In this study, we report that RAR gamma subgroup-specific agonists are the most potent inhibitors of serum and serotonin VSMC proliferation, as compared with other RAR pan-agonists and naturally occurring retinoids tested. Our results indicate that RAR gamma subgroup-specific agonists should be assessed further in in vivo models of neointimal proliferation.
Insights
Synthetic retinoids, particularly RAR gamma agonists, show potent inhibition of vascular smooth muscle cell proliferation, offering a promising avenue for restenosis treatment with potentially fewer side effects than traditional retinoids.
Area of Science:
- Vascular Biology
- Pharmacology
- Molecular Medicine
Background:
- Restenosis involves complex neointimal proliferation, requiring multifaceted interventional strategies.
- Retinoids are effective biologic response modifiers for neointimal proliferation but often cause adverse effects.
- All-trans-retinoic acid acts via RARs and RXRs; synthetic retinoids offer specificity and reduced toxicity.
Purpose of the Study:
- To investigate the efficacy of synthetic retinoids in inhibiting vascular smooth muscle cell (VSMC) proliferation.
- To compare the potency of different retinoid receptor agonists against serum- and serotonin-induced VSMC proliferation.
Main Methods:
- Evaluation of synthetic retinoids, including RAR gamma subgroup-specific agonists, on VSMC proliferation.
- Comparison with pan-RAR agonists and naturally occurring retinoids as controls.
- Assessment of inhibition against both serum- and serotonin-induced VSMC proliferation.
Main Results:
- All-trans-retinoic acid demonstrated inhibitory effects on VSMC proliferation at nanomolar concentrations.
- RAR gamma subgroup-specific agonists were identified as the most potent inhibitors of VSMC proliferation.
- These specific agonists outperformed other RAR pan-agonists and natural retinoids tested.
Conclusions:
- RAR gamma subgroup-specific agonists represent a highly effective class of compounds for inhibiting VSMC proliferation.
- These findings suggest potential therapeutic applications for RAR gamma agonists in managing restenosis.
- Further in vivo studies are warranted to validate the efficacy of RAR gamma agonists in neointimal proliferation models.
More Related Videos
06:14Murine Aortic Crush Injury: An Efficient In Vivo Model of Smooth Muscle Cell Proliferation and Endothelial Function
Published on: June 11, 2017
08:28Isolation of Primary Patient-specific Aortic Smooth Muscle Cells and Semiquantitative Real-time Contraction Measurements In Vitro
Published on: February 15, 2022
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:28Drugs Acting on Autonomic Ganglia: Blockers
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:23Antihypertensive Drugs: Vasodilators
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...